These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1006 related items for PubMed ID: 18568770

  • 1. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC.
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [Abstract] [Full Text] [Related]

  • 2. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 3. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF.
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM.
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [Abstract] [Full Text] [Related]

  • 6. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M, Rody A.
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun 01; 126(2):146-54. PubMed ID: 16621229
    [Abstract] [Full Text] [Related]

  • 10. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M, Yamashiro H, Tsuji W.
    Breast Cancer; 2009 Jun 01; 16(3):207-18. PubMed ID: 19259765
    [Abstract] [Full Text] [Related]

  • 11. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT.
    Breast Cancer Res Treat; 2008 Dec 01; 112 Suppl 1():25-34. PubMed ID: 19101792
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C.
    Surg Oncol; 2008 Aug 01; 17(2):113-28. PubMed ID: 18178077
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J, Pritchard K, Goss P.
    Breast; 2007 Dec 15; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [Abstract] [Full Text] [Related]

  • 18. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
    Dixon JM.
    Breast; 2008 Aug 15; 17(4):353-60. PubMed ID: 18490163
    [Abstract] [Full Text] [Related]

  • 19. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 15; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.